Securities Fraud Investigation Into Erasca, Inc. (ERAS) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
The Law Offices of Frank R. Cruz announces an investigation of Erasca, Inc. (“Erasca” or the “Company”) (NASDAQ: ERAS) on behalf of investors concerning the Company’s possible violations of federal securities laws.
IF YOU ARE AN INVESTOR WHO LOST MONEY ON ERASCA, INC. (ERAS), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS.
What Is The Investigation About?
On April 27, 2026, before market hours, Erasca disclosed that it had received a letter from legal counsel for Revolution Medicines, Inc. (“RevMed”) alleging that Erasca’s drug candidate, ERAS-0015, infringes a RevMed patent and is connected to alleged trade secret misappropriation. RevMed also claimed that Erasca had “improperly compared preclinical data of ERAS-0015 and RMC-6236 in public disclosures” and demanded Erasca cease making “deceptive and untrue comparative statements comparing ERAS-0015 and RMC-6236.”
